Phathom Pharmaceuticals appears to be at a critical commercial inflection point, with quarterly revenue accelerating from near-zero to $74.3M and operating losses narrowing dramatically as the commercial launch gains traction. However, the investment case is h...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.21-19.6% vs -$0.18 | $74M+1.4% vs $73M |
Q2 2026 Apr 30, 2026 | -$0.37-37.0% vs -$0.27 | $58M+4.3% vs $56M |
Q1 2026 Feb 26, 2026 | -$0.29+9.2% vs -$0.32 | $58M+0.7% vs $57M |
Q4 2025 Oct 30, 2025 | -$0.41-2.5% vs -$0.40 | $50M+5.3% vs $47M |
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume of 2071393 shares traded. The stock had previously closed at $8.16. Analyst Ratings Changes Several equities analysts have recently weighed
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
Benchmark PHAT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Phathom Pharmaceuticals, Inc. (PHAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.99 | $557.09M | -2.31 | 216.93% | -126.35% | — | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $4.27 | $702.9M | 28.47 | -15.72% | 33.36% | — | — | |
| $138.70 | $8.92B | -67.66 | -89.41% | 29.4% | 12.03% | — |
Phathom Pharmaceuticals, Inc. (PHAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Phathom Pharmaceuticals, Inc. (PHAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 23, 2026·SEC
May 21, 2026·SEC
Get notified when PHAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Phathom Pharmaceuticals, Inc. (PHAT) stock FAQ — growth, dividends, profitability & financials explained
Phathom Pharmaceuticals, Inc. (PHAT) reported $239.7M in revenue for fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 216.9% over the past year. This is strong growth.
Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $81.5M for fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $36.5M in fiscal year 2025, likely due to heavy capital investments.
